I will eat some crow tonight.....
but (imo) we are not that as rosy as some are making it out to be
I still fear a breakdown under .03 could send us sub penny
either way I feel upward pressure at around a dime will leave us hung
most stronglongs should have averaged down under a dime by now
and the hype around the November Ballot? I just don't see how CBIS is poised to react to a positive swing?
Explain to me how CBIS will profit from the California Vote?
operations or distribution at this time are nonexistent
I hope we get some traction within the next thirty days
(I have spoken to insiders @ Harborside (the largest dispensary in CA, (ithink)) and they don't claim to know what CBIS is...but their interest was peaked)
I would like to see CBIS products & marketing rather than statements
You fellows realize these statements regarding research and market conditions (not cbis's research or condition - btw) cost a lot of $ to produce
On May 14, 2010, the Company issued 400,000 restricted common shares at $0.135 per share to acquire the assets of Rockbrook Inc. Subsequent the quarter-end, on July 27, 2010, the Company signed a mutual termination agreement to reverse the acquisition and cancel the shares. (see Note 7 to Financial Statements, p.F-10).
On August 19, 2010, the Company signed a license agreement with RockBrook Inc, a medical marijuana medicines company. RockBrook has been granted the full latitude and rights to manufacture, develop, produce, distribute and sell products developed from, or based on, Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado. Under the agreement RockBrook will pay Cannabis Science an initial licence fee of $25,000, payable within the first year. RockBrook will also pay the Company a quarterly royalty payment of 50% of all positive revenues derived from the the Company Brand of Pharmaceutical Products. Additionally, in the event RockBrook executes any sublicensing agreements, Cannabis Science is entitled to royalty payments of 50% of all positive revenues received by the licensee for sales of any Cannabis Science Brand of Pharmaceutical Products. Within two years RockBrook is expected to invest a minimum of $250,000 in research and development for the Cannabis Science Brand of Pharmaceutical Products and will also pay the Company a renewable licence fee, payable annually on the anniversary of the execution of this agreement. The first anniversary payment will be $25,000, the second $50,000, third $75,000 and fourth $100,000. The fifth and subsequent anniversary payments will be $150,000.
